Trials / Terminated
TerminatedNCT01362348
12 Week Patient Study in Neovascular Age-related Macular Degeneration (AMD)
An Open-label, Phase 2a Study to Evaluate Pazopanib Eye Drops Administered for 12 Weeks to Patients With Neovascular Age-related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 19 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this 12 week, open-label study is to investigate the safety and efficacy of a single dose regimen of pazopanib eye drop for neovascular AMD.
Detailed description
MD7114987 is a Phase 2a study designed to determine whether pazopanib eye drops have the potential to reduce retinal edema and maintain or improve visual acuity in persons with a previously untreated subfoveal choroidal neovascularization (CNV) lesion secondary to age-related macular degeneration (AMD) and to further characterize the safety and tolerability of pazopanib eye drops administered over a 12-week period.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | pazopanib eye drops | 10 mg/mL (1 drop) four times daily |
Timeline
- Start date
- 2011-07-07
- Primary completion
- 2012-04-16
- Completion
- 2012-04-16
- First posted
- 2011-05-30
- Last updated
- 2017-09-21
- Results posted
- 2017-08-21
Locations
15 sites across 3 countries: United States, France, Germany
Source: ClinicalTrials.gov record NCT01362348. Inclusion in this directory is not an endorsement.